Arcus Biosciences (RCUS) Price & Analysis

Compare

488 Followers

RCUS Stock Chart & Stats

Day’s Range― - ―

52-Week Range$6.50 - $18.98

Previous CloseN/A

Volume107.84K

Average Volume (3M)761.32K

Market Cap

$1.15B

Enterprise Value$64.91M

Total Cash (Recent Filing)$911.00M

Total Debt (Recent Filing)$109.00M

Price to Earnings (P/E)―

Beta2.02

Next Earnings

Nov 11, 2025

EPS Estimate

-1.28

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.00

Shares Outstanding106,430,980

10 Day Avg. Volume642,114

30 Day Avg. Volume761,321

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.06

Enterprise Value/Revenue0.25

Enterprise Value/Gross Profit0.25

Enterprise Value/Ebitda-0.23

Forecast

1Y Price Target

$30.70

Price Target Upside165.57% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Clinical ProgressThe PEAK-1 trial has initiated enrollment and will evaluate casdatifan and cabozantinib in patients with advanced or metastatic clear cell renal cell carcinoma, indicating progress in research and development.

Financial PositionArcus Biosciences ended the quarter with significant cash and investments, expected to fund operations through key initial readouts, providing a strong financial position.

Product DifferentiationNew analysis supports the clinical relevance of erythropoietin suppression by casdatifan, which differentiates it from competitors, bolstering confidence in its potential.

Bears Say

Commercial ChallengesSkepticism has weighed on sentiment due to Gilead's commercial opt-out and overall uncertainty.

Competitive PressuresDifficulties competing with established players like Merck and Bristol and the considerable cost of running necessary studies pose challenges.

Market SkepticismArcus faces challenges in achieving its vision due to prescriber inertia and strong skepticism towards its PD-1 zimberelimab.

Arcus Biosciences News

Gilead and Arcus Biosciences’ Promising Phase 3 Lung Cancer Study: Market Implications

Gilead Sciences (($GILD)), Arcus Biosciences (($RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. In...

15d ago

GILD

RCUS

Gilead and Arcus Advance Promising Colorectal Cancer Study

Gilead Sciences (($GILD)), Arcus Biosciences (($RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead...

29d ago

GILD

RCUS

Gilead and Arcus Biosciences’ Promising Study on Advanced Gastrointestinal Cancers

Gilead Sciences (($GILD)), Arcus Biosciences (($RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. The...

29d ago

GILD

RCUS

Positive Buy Rating for Arcus Biosciences Driven by Promising Trial Developments and Strategic Outlook

H.C. Wainwright analyst Emily Bodnar has maintained their bullish stance on RCUS stock, giving a Buy rating today....

30d ago

RCUS

Arcus Biosciences Reports Strong Q2 2025 Results

Arcus Biosciences ( ($RCUS) ) has released its Q2 earnings. Here is a breakdown of the information Arcus...

1M ago

RCUS

Arcus Biosciences reports Q2 EPS 0c, may not compare to consensus ($1.17)

Reports Q2 revenue $160M, may not compare to consensus $32.86M. The increase in revenue was driven by a...

1M ago

RCUS

Arcus Biosciences Advances Phase 1 Study of AB521 in Cancer Treatment

Arcus Biosciences (($RCUS)) announced an update on their ongoing clinical study. Arcus Biosciences is currently conducting a Phase...

1M ago

RCUS

Arcus Biosciences’ Promising Phase 3 Trial for Pancreatic Cancer

Arcus Biosciences (($RCUS)) announced an update on their ongoing clinical study. Arcus Biosciences is conducting a Phase 3...

1M ago

RCUS

Gilead and Arcus Advance Immunotherapy Study in Lung Cancer

Gilead Sciences (($GILD)), Arcus Biosciences (($RCUS)), Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead...

1M ago

GILD

RCUS

Arcus Biosciences Advances Cancer Treatment with AB801 Study

Arcus Biosciences (($RCUS)) announced an update on their ongoing clinical study. Arcus Biosciences is conducting a Phase 1/1b...

1M ago

RCUS

Arcus Biosciences Advances Cancer Treatment with AB598 Study

Arcus Biosciences (($RCUS)) announced an update on their ongoing clinical study. Arcus Biosciences is conducting a Phase 1/1b...

1M ago

RCUS

Arcus Biosciences quemliclustat granted orphan drug designation by FDA

Arcus Biosciences (RCUS) announced that quemliclustat, an investigational small molecule CD73 inhibitor, was granted orphan drug designation by...

2M ago

RCUS

Arcus Biosciences treatment of pancreatic cancer granted orphan designation

Arcus Biosciences (RCUS)’ quemliclustat was granted FDA orphan designation as a treatment of pancreatic cancer, according to a...

2M ago

RCUS

Arcus Biosciences presented data for casdatifan plus cabozantinib

Arcus Biosciences (RCUS) presented the first data for casdatifan plus cabozantinib in an oral presentation by Dr. Toni...

3M ago

RCUS

RCUS FAQ

What was Arcus Biosciences Inc’s price range in the past 12 months?

Arcus Biosciences Inc lowest stock price was $6.50 and its highest was $18.98 in the past 12 months.

What is Arcus Biosciences Inc’s market cap?

Arcus Biosciences Inc’s market cap is $1.15B.

When is Arcus Biosciences Inc’s upcoming earnings report date?

Arcus Biosciences Inc’s upcoming earnings report date is Nov 11, 2025 which is in 66 days.

How were Arcus Biosciences Inc’s earnings last quarter?

Arcus Biosciences Inc released its earnings results on Aug 06, 2025. The company reported $0 earnings per share for the quarter, beating the consensus estimate of -$1.126 by $1.126.

Is Arcus Biosciences Inc overvalued?

According to Wall Street analysts Arcus Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Arcus Biosciences Inc pay dividends?

Arcus Biosciences Inc does not currently pay dividends.

What is Arcus Biosciences Inc’s EPS estimate?

Arcus Biosciences Inc’s EPS estimate is -1.28.

How many shares outstanding does Arcus Biosciences Inc have?

Arcus Biosciences Inc has 106,430,980 shares outstanding.

What happened to Arcus Biosciences Inc’s price movement after its last earnings report?

Arcus Biosciences Inc reported an EPS of $0 in its last earnings report, beating expectations of -$1.126. Following the earnings report the stock price went down -2.213%.

Which hedge fund is a major shareholder of Arcus Biosciences Inc?

Currently, no hedge funds are holding shares in RCUS

Arcus Biosciences Stock Smart Score

Neutral

Fundamentals

Return on Equity

-50.34%

Trailing 12-Months

Asset Growth

-9.36%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Arcus Biosciences Inc

Arcus Biosciences (RCUS) is a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies. The company specializes in creating treatments that harness the body's immune system to combat various forms of cancer, particularly through its proprietary drug candidates targeting key pathways in the tumor microenvironment. Arcus is engaged in the research and development of its lead programs, which include both immunotherapy and targeted therapy options, aiming to improve patient outcomes in oncology.

Arcus Biosciences (RCUS) Earnings & Revenues

Historic Earnings Reports

RCUS Company Deck

RCUS Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted Arcus Biosciences' strong financial position and strategic focus on the casdatifan program, supported by significant investor and investigator enthusiasm. However, there were challenges related to pipeline prioritization and a decline in quarterly revenue.View all RCUS earnings summaries

RCUS Stock 12 Month Forecast

Average Price Target

$30.70

▲(165.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","53":"$53","17.75":"$17.75","29.5":"$29.5","41.25":"$41.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":52,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$52.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$30.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,17.75,29.5,41.25,53],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.81,13.978461538461538,17.146923076923077,20.315384615384616,23.48384615384615,26.652307692307694,29.82076923076923,32.989230769230765,36.15769230769231,39.326153846153844,42.494615384615386,45.66307692307692,48.83153846153846,{"y":52,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.81,12.34,13.870000000000001,15.4,16.93,18.46,19.990000000000002,21.520000000000003,23.05,24.58,26.11,27.64,29.17,{"y":30.7,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,10.81,10.901538461538461,10.993076923076924,11.084615384615384,11.176153846153847,11.267692307692307,11.35923076923077,11.45076923076923,11.542307692307693,11.633846153846154,11.725384615384616,11.816923076923077,11.908461538461538,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.12,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.42,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.94,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.89,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.9,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.89,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.22,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.16,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.81,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >